WHAT IS PHASIX™ ST MESH? 

Phasix™ ST Mesh combines two market-leading technologies into one product: monofilament resorbable Phasix™ Mesh and a proven hydrogel barrier based on Sepra^® technology.

Click Here to learn more about Phasix™ Mesh

THE NEXT PHASE IN HERNIA REPAIR

Repairs. ^*

The open monofilament mesh structure provides early integration and repair strength.¹
 

Remodels. ^*

Vascular integration and incorporation continues, with abundant mature collagen at 52 weeks. Gradually transfers load to native tissue over time. ¹
 

Restores. ^*

As Phasix™ Mesh is remodeled, it is replaced with functional tissue, ultimately resulting in a strong repair at one year.¹

^{1 Preclinical data on file at C. R. Bard, Inc. Phasix™ ST Mesh shows similar mechanical strength over time to Phasix™ Mesh in a preclinical model. Results may not correlate to clinical performance in humans.
2 Preclinical data on file. Results may not correlate to clinical performance in humans.
3 Deeken CR, Matthews BD. “Characterization of the mechanical strength, resorption properties, and histologic characteristics of a fully absorbable material (Poly-4-hydroxybutyrate—Phasix™ Mesh) in a porcine model of hernia repair.” ISRN Surgery 2013; 1-12.
4 Deeken CR, Abdo MS, Frisella MM, Matthews BD. “Physicomechanical evaluation of absorbable and nonabsorbable barrier composite meshes for laparoscopic ventral hernia repair.” Surgical Endoscopy 25.5 (2010): 1541-552.
5 Estimated from Standard Curve in manuscript (Martin, et al. JSR 2013).}

WHY PHASIX™ ST?

^{1 Preclinical data on file at C. R. Bard, Inc. Results may not correlate to clinical performance in humans.
2 Nguyen PT, Asarias JR, Pierce LM. “Influence of a new monofilament polyester mesh on inflammation and matrix remodeling.” J Invest Surg 2012; 25: 330
3 Bryan N, Ahswin H, Smart NJ, Bayon Y, Hunt JA. “In vitro activation of human leukocytes in response to contact with synthetic hernia meshes.” Clin Biochem 2012; 45: 672
4 Aydinuraz K, Agalar C, Agalar F, Ceken S, Buruyurek N, Voral T. “In vitro S. epidermidis and S. aureus adherence to composite and lightweight polypropylene grafts.” J Surg Res 2009; 157: e79.
5 Amid PK, Shulman AG, Lichtenstein IL, Hakaha M. “Biomaterials for abdominal wall hernia surgery and principles of their applications.” Langenbecks Archive Chir 1994; 379(3): 168-71.
6 Klinge U, Junge B, Spellerberg B, Piroth C, Klosterhalfen B, Schumpelick V. “Do multifilament alloplastic meshes increase the infection rate? Analysis of the polymeric surface, the bacterial adherence, and the in vivo consequences in a rat model.” J Biomed Mater Res (Appl Biomater) 2002; (63): 765-771.
7 Long-term clinical data not yet available.}

MATERIAL STRUCTURE¹

Monofilament mesh designs have been deemed more biocompatible and less susceptible to bacterial adherence and colonization.^2,3,4,5,6 

^{1 Preclinical data on file at C. R. Bard, Inc. Results may not correlate to clinical performance in humans.
2 Nguyen PT, Asarias JR, Pierce LM. “Influence of a new monofilament polyester mesh on inflammation and matrix remodeling.” J Invest Surg 2012; 25: 330
3 Bryan N, Ahswin H, Smart NJ, Bayon Y, Hunt JA. “In vitro activation of human leukocytes in response to contact with synthetic hernia meshes.” Clin Biochem 2012; 45: 672
4 Aydinuraz K, Agalar C, Agalar F, Ceken S, Buruyurek N, Voral T. “In vitro S. epidermidis and S. aureus adherence to composite and lightweight polypropylene grafts.” J Surg Res 2009; 157: e79.
5 Amid PK, Shulman AG, Lichtenstein IL, Hakaha M. “Biomaterials for abdominal wall hernia surgery and principles of their applications.” Langenbecks Archive Chir 1994; 379(3): 168-71.
6 Klinge U, Junge B, Spellerberg B, Piroth C, Klosterhalfen B, Schumpelick V. “Do multifilament alloplastic meshes increase the infection rate? Analysis of the polymeric surface, the bacterial adherence, and the in vivo consequences in a rat model.” J Biomed Mater Res (Appl Biomater) 2002; (63): 765-771.
7 Long-term clinical data not yet available.}

TISSUE INCORPORATION

At 12 weeks, Phasix™ ST Mesh is well incorporated with new vascularized tissue and minimal inflammatory response. A new peritoneal layer has been laid down in place of the ST barrier. By 48 weeks, Phasix™ ST Mesh continues to be remodeled and is replaced with mature functional tissue.¹

^{1 Preclinical data on file; results may not correlate to clinical performance in humans.}